Waldenstro¨m macroglobulinemia (WM) is a distinct indolent B-cell lymphoproliferative malignancy characterized by IgM paraproteinemia. Although the disease is sensitive to chemo-immunotherapy, it remains incurable and affected patients have a median survival of 5-10 years. Risk stratification in newly diagnosed patients should start with a prognostic evaluation based on the International Prognostic Scoring System for WM (IPSSWM) to identify those patients in whom particularly poor survival with chemotherapy is expected and in whom alternative treatment strategies, such as hematopoietic cell transplantation (HCT), should be considered. High-dose chemotherapy followed by autologous HCT (auto-HCT) results in disease-free survival of 45-65% at 5 years, but is unlikely to be curative. Chemosensitive disease at the time of auto-HCT is the most important prognostic factor for response rate and overall survival. Allogeneic donor HCT may offer a unique immunemediated GVL effect with a plateau in relapse rates and potential for extended disease-free survival. The risk of allogeneic HCT complications is justified in HCT-eligible patients whose expected survival is o5 years. Here, we present the advances in non-transplant strategies and the therapeutic role of transplant, and suggest a treatment algorithm for selecting a HCT strategy while adhering to current evidence supporting autologous and allogeneic donor HCT for WM.
Introduction
Waldenstro¨m macroglobulinemia (WM) is a clonal B-cell lymphoproliferative disorder characterized by accumulation of CD19 þ CD20 þ lymphoplasmacytic cells and production of a pentameric IgM monoclonal protein. 1 The
World Health Organization includes WM in a broader category of lymphoplasmacytic lymphoma but these two entities are not synonymous. WM must also be differentiated from plasmacytoid variants of lymphomas, IgM producing marginal zone lymphoma, B-cell chronic lymphocytic leukemia and IgM myeloma. 2 The consensus group of the International Workshop on WM in 2007 redefined WM as a distinct clinicopathologic entity, characterized by BM infiltration by lymphoplasmacytic lymphoma and IgM monoclonal gammopathy.
3 WM is a rare disease with a long natural history. Its incidence is 0.5 cases per 100 000 population, with half of affected patients older than 60 years of age. The clinical presentation is highly variable, and a third of patients may be asymptomatic at diagnosis. When WM progresses, it can manifest as constitutional symptoms, varying degrees of anemia and thrombocytopenia related to marrow infiltration, bulky tumor lymphadenopathy or organomegaly, neuropathy, amyloidosis, cold-agglutinin anemia, and symptoms related to hyperviscosity and Ig deposition. This review first summarizes current non-transplant therapies, and then focuses on the indications for and outcomes of hematopoietic cell transplantation (HCT) in WM. Finally, a treatment algorithm incorporating HCT for patients with relapsed disease is suggested.
First-line therapy for WM
WM is considered highly sensitive to chemotherapy, though treatment is typically reserved for symptomatic patients, analogous to other indolent lymphomas. The decision to treat and the choice of first-line therapy is directed mainly by patient age, presence of comorbidities, disease signs and symptoms, pace of progression and overall functional status of the patient. The aim of first-line therapy is to eliminate or improve symptoms, enhance quality of life, prevent organ damage, delay disease progression and minimize toxicity. First-line therapies include alkylating agents or nucleoside-analogues, often combined with the anti-CD20 MoAb rituximab, and sometimes corticosteroids. Although current first-line therapies are unable to cure WM, they are associated with remission rates of 40-90% and median survival times of about 5 years from the time of initial treatment. 4, 5 For the majority of patients, responses are incomplete but durable, and about 10% of patients are alive at 15 years. The Consensus Panel of the International Workshop on WM concluded that individualized approaches to first-line therapy are necessary, given the lack of evidence favoring any particular treatment option. 4 The International Prognostic Scoring System for WM (IPSSWM) has been developed as an easily applied clinical tool to predict survival outcomes of individual patients enabling a riskadapted therapeutic approach. 6 The IPSSWM utilizes five readily available clinical and laboratory features (age465 years, Hbo11.5 g/dL, plts counto100 000/mm 3 , b2M43 g/dL and serum monoclonal protein 47.0 g/dL) that stratify patients treated with first-line therapy into three risk groups. Each risk group is associated with widely disparate 5-year overall survival (OS) rates that range from 87% for low-risk, to 68% for intermediate-risk and to 36% for highrisk patients (Figure 1 ). This divergent survival was observed irrespective of first-line chemotherapy used (alkylating agent or fludarabine). The IPSSWM was validated by Kastritis et al. 7 in an independent cohort that included over 350 patients with WM, and remained a robust system even in patients receiving first-line treatment with rituximabbased regimens. This study also demonstrated that serum lactate-dehydrogenase (LDH) was able to divide high-risk patients into two subgroups with significantly different outcomes; the median OS was 94 months (95% CI: 69.5-118.0 months) for patients with a normal LDH and 35 months (95% CI: 13.7-56.0 months) for those with an elevated LDH (Po0.01). 7 Thus, high IPSSWM score and elevated serum LDH define a subset of patients with particularly poor survival of o3 years and for whom innovative treatment strategies are needed.
Therapy for relapsed disease and novel agents
Therapeutic approaches for relapsed disease are widely variable and include combined chemo-immunotherapies; alkylating agents, fludarabine and more recently bendamustine, alone or in combination with rituximab and corticosteroids have shown considerable activity. 4 Remissions are often partial and progression-free survival (PFS) can be extended by years. Many novel therapeutic agents have been used in Phase 2 clinical trials and several showed promising activity deserving further clinical investigations either alone or in combinations (Table 1) 8,9 (reviewed in Rourke et al., 10 Vijay and Gertz 11 and Treon 5 ). Future application of some of these agents, particularly lenalidomide, thalidomide and bortezomib, may include peritransplant use. In selecting an effective salvage regimen, the approach to potential transplant candidates requires careful consideration to limit hematopoietic cell depletion, protect organ function and reduce the risk of secondary malignancies including transformation to aggressive lymphoma and treatment related myelodysplastic syndrome.
Is there a role for HCT in WM?
Given the chemosensitivity of this disease, myeloablative chemotherapy with or without total body irradiation (TBI) Transplantaion for Waldenström macroglobulinemia V Bachanova and LJ Burns followed by autologous HCT (auto-HCT) has been increasingly used for WM. More recently, allogeneic HCT (allo-HCT) has become a curative option for patients with other low-grade lymphoid malignancies. Recent studies show that auto-or allo-HCT may result in disease control or extensive PFS for patients with high-risk WM (Tables 2 and 3 ). Here we examine the evidence for the benefit of HCT in WM, specifically comparing auto-and allo-HCT outcomes, impact of conditioning regimens, and suggest an algorithm for patient selection and therapy.
Auto-HCT for WM
Several clinical studies have examined the feasibility and safety of high-dose conditioning regimens followed by auto-HCT in patients with high-risk WM. [12] [13] [14] [15] [16] [17] [18] [19] [20] A total of 24 previously published cases, reviewed by Anagnostopoulos et al. 12 included heavily pretreated patients treated with a variety of conditioning regimens, including melphalan 200 mg/m 2 , thiotepa/BU/CY, or CY with TBI. These regimens were relatively well tolerated with low treatment-related mortality, manageable non-hematological toxicities and promising response rates. Results of published series with more than six patients are shown in Table 2 . The largest single center study is the French report of 19 patients in whom a 1-year treatment-related mortality of 6% and PFS of 45% was observed. 15 Although the length of follow-up was relatively short (range from 0.8 to 2.8 years), these results suggested that further exploration of auto-HCT for relapsed WM was warranted. Anagnostopoulos et al., 16 on behalf of the Center for International Blood and Marrow Transplant Research, also reported a series of 36 patients of whom 10 were recipients of high-dose chemotherapy followed by peripheral blood auto-HCT. Results showed a promising 3-year OS of 70% and a PFS of 65%, with 100-day non-relapse mortality and relapse rates of 11 and 29%, respectively. Long-lasting CRs were observed in several patients. An analysis of the UK transplant registry data for lymphoplasmacytic lymphoma showed an encouraging 4-year DFS of 43% and OS of 73% for auto-HCT. 17 The largest study to date of auto-HCT analyzed 158 adults with WM reported to the European Marrow and Blood Transplant Registry (EBMTR) between 1991-2005. 18 At the time of transplant, over 90% of patients had chemosensitive disease and most were within 2 years of initial diagnosis. Almost half of the patients received BEAM and a third received TBI-based conditioning. At 2 years, 68% of patients were alive; PFS was 61% at 3 years and 39% at 5 years, suggesting no plateau on the The main factors impacting treatment-related mortality were poor performance status at the time of transplant. In multivariate analysis, inferior OS was significantly associated with at least three lines of previous treatment, chemo-refractory disease, male sex and age 450 years. Given the success of using high-dose conditioning therapy followed by auto-HCT in relapsed WM, some investigators suggested that this approach be applied earlier in the course of the disease. Reports of small pilot series have demonstrated the feasibility and efficacy of auto-HCT as part of first-line therapy; however, the follow-up times were short and number of patients were small. 19, 20 In a study by Dreger and Schmitz, 12 patients were treated with dexamethasone plus BEAM mobilization followed by a conditioning regimen of TBI/high-dose CY, and then rescued with grafts purged by B cell-negative or CD34 þ selection. 19 Only 2 of 9 patients achieved a negative IF, and 6 patients subsequently relapsed at a median time of 69 months. A second study by Caravita et al. 20 piloted a treatment strategy combining rituximab and CHOP (R-CHOP) followed by CY mobilization and subsequent upfront consolidation with auto-HCT using high-dose melphalan conditioning. At a median follow-up of 66 months, all 5 patients maintained a stable PR without need for re-treatment. Given these results, upfront auto-HCT warrants further testing with the development of welldesigned prospective clinical trials for high-risk WM patients. Such trials are particularly relevant for diseases with a long median survival, such as WM, and because of the life-long risk of developing post transplant secondary malignancies and late transplant-related toxicities.
Allo-HCT for WM
Allo-HCT is a curative therapeutic option for patients with low-grade and indolent lymphomas and has been more 
18,24
Transplantaion for Waldenström macroglobulinemia V Bachanova and LJ Burns widely used for patients with WM (Table 3) . Initial single institution series included mainly heavily pretreated patients and used myeloablative conditioning. In the French experience, at a median follow-up of 1.5 years, 6 of 10 patients with advanced WM remained disease-free, whereas 4 died from transplant complications. 15 A report from Canada demonstrated that 4 of 5 patients remained free of disease at a median follow-up of 32 months and demonstrated progressive, delayed decline of IgM over 6 months, which is suggestive of an active GVL effect. 21 A retrospective WM analysis reported to the Center for International Blood and Marrow Transplant Research included 26 allo-HCT recipients. 16 Half of the enrolled patients were resistant to salvage chemotherapy and 52% received TBI-based myeloablative conditioning; 19% received a reduced intensity conditioning (RIC) regimen. Results demonstrated unacceptably high non-relapse mortality (40%) and persistent risk of relapse (29%) for patients with chemorefractory WM, with 3-year OS and PFS of 46% and 31%, respectively.
Reducing the conditioning regimen intensity before allo-HCT to decrease toxicity, while allowing engraftment and a subsequent GVL effect, has led to promising outcomes in several studies. [23] [24] [25] Maloney et al. 22 described 13 patients who underwent allo-HCT with RIC consisting of fludarabine and low-dose TBI (2 Gy) with an OS rate of 60%. An overall response rate of 91% and PFS of 60% suggested promising long-term outcomes. Similarly promising are the UK registry and French results of 5-year OS of 73 and 67%, and DFS of 43 and 58%, respectively, when RIC was used in about half of the patients. 17, 24 Importantly, RIC allowed investigators to increase the pool of eligible patients to include elderly patients and those with pre-HCT comorbidities. The EBMTR series, the largest published analysis to date, compared outcomes based on conditioning regimen intensity for 86 patients with advanced WM treated with allo-HCT. 25 Most patients received RIC (n ¼ 49) and in vivo or ex vivo T-cell depleted grafts (n ¼ 51); eight patients had failed prior auto-HCT, and almost 70% of WM patients were chemosensitive at the time of allo-HCT. The median time to response was 6 months, and 15 patients achieved a CR confirmed by IF. Very good PR, PR and stable disease were observed in 13, 17 and 6 patients, respectively. Treatment-related mortality was modestly reduced with RIC (23%) compared with myeloablative conditioning (33%). The relapse rate at 3 years was 25% for RIC and 11% for myeloablative conditioning . Although a third of patients were high risk according to the IPSSWM staging system and expected to have an estimated survival of 3 years, OS was 75% at a median follow-up of 50 months. The estimated 5-year OS and PFS rates were 62% and 56%, respectively, with no difference in either outcome based on conditioning intensity ( Figure 2B ). Patients with poor performance status at the time of HCT had significantly inferior PFS. Thus, given the limited available data and number of patients studied, the impact of the intensity of the conditioning regimen on outcomes following allo-HCT remains an unanswered question.
What is the evidence for a GVL effect following allo-HCT?
Data on allo-HCT with WM are limited, but several indicators suggest a potent GVL effect in this disease. The Seattle group demonstrated that those patients who developed extensive chronic GVHD had longer survival and protection from relapse. 22 These results were confirmed in the EBMTR series, where chronic GVHD was also associated with a lower relapse rate and trend for improved DFS. 24 The observation that alemtuzumab and T cell depletion increased the relapse rate after HCT provides additional evidence for a beneficial T-cell mediated GVL effect. A second line of evidence comes from an analysis of EBMTR data on donor lymphocyte infusion. 24 Twenty-one patients received donor lymphocyte infusion, 6 for mixed Figure 3 Proposed algorithm for treating patients with relapsed WM in whom transplant is considered.
Transplantaion for Waldenström macroglobulinemia V Bachanova and LJ Burns chimerism and 14 for persistent or relapsed disease post allo-HCT. The overall response rate to donor lymphocyte infusion was 80% (CR (n ¼ 7), PR (n ¼ 4)), with only two patients failing to respond. Importantly, the OS and DFS survival curves of patients treated with allo-HCT reached a plateau over time, in contrast to the outcomes from auto-HCT, where late relapses continued to occur. In aggregate, recent evidence suggests that a potent GVL effect may offer protection from relapse for selected patients with relapsed WM.
Summary and recommendations for incorporating HCT into a treatment algorithm
WM is an indolent lymphoproliferative disorder with survival measured in years and for which the general goal of therapy is to reduce symptoms. The IPPSWM scoring system and LDH are useful tools to identify those patients in whom particularly poor survival with chemotherapy can be expected and thus confer the opportunity to consider alternative treatment strategies, such as HCT. Alkylating agents deplete stem cells and should be used cautiously in patients who may be eligible for auto-HCT. Accordingly, high-dose therapy with auto-HCT or allo-HCT may be appropriate early in the course of symptomatic relapsed high-risk WM; however, specific guidelines as to the type or timing of HCT in WM are lacking. 25 Given the limited evidence and modest number of patients with WM who have undergone HCT, we provide a conservative treatment algorithm ( Figure 3 ) that incorporates current published knowledge and proposes selecting patients with relapsed disease for auto-and allo-HCT based on IPSSWM risk assessment and sensitivity to previous therapy. Auto-HCT should be reserved for recurrent chemotherapy responsive WM, particularly in low-risk patients in whom duration of the first remission is o2 years and in patients with intermediate or high IPSSWM (Figure 3) . 25 Importantly, the role of auto-HCT for primary consolidation in the first remission of high-risk WM is not clear and could be considered only in the setting of a controlled clinical trial. We also recommend avoiding auto-HCT in patients with chemorefractory disease and those heavily pretreated patients with more than three lines of previous therapy, as these features lead to inferior survival, higher relapse rates and increased incidence of secondary malignancies, thus undermining the benefits of auto-HCT. Younger, relatively healthy patients with short remissions, high-risk IPSSWM score and elevated LDH could be considered for allo-HCT with curative intent. Increasing experience with RIC conditioning suggests extending the benefit of allo-HCT to the elderly, those with comorbidities and patients who have relapsed following autologous HCT, offering the possibility of prolonged PFS for patients with limited treatment options. However, until more experience is gained with allo-HCT, particularly in high-risk patients and those with comorbidities, allo-HCT should be performed in experienced transplant centers within the context of controlled clinical trials. More data on HCT outcomes are clearly needed in this uncommon malignancy, exemplifying the enormous value of the transplant registry databases as highlighted by the recent reports from EBMTR, which demonstrated promising long-term PFS in HCT recipients.
Research in WM must continue to focus on applying molecular analysis and genetics to identify predictive biomarkers and therapeutic targets. More studies are needed to test novel agent combinations and incorporate immuno-therapeutics into transplant protocols, both pre transplant and as post transplant consolidation or maintenance. Growing clinical experience using HCT in WM, including the use of RIC regimens and advances in supportive care, offer greater hope for more patients.
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